Libya pharmaceutical system is under pressure

Libya spent around LYD 11.8 billion on the pharmaceutical public sector between 2022 and 2025, yet shortages, expired stock and weak oversight persisted, as reported by Libya Gazette on June 15th.

A joint Audit Bureau and National Anti-Corruption Commission report found that spending rose sharply in 2023 before falling again in 2025, without a clear link to actual healthcare needs.

The report points to a fragmented procurement system, with more than 25 bodies involved in buying medicines and no unified national framework for estimating demand, this has produced duplicated orders, surplus stock, missing essential drugs and limited accountability while a small number of agents appear to dominate parts of the pharmaceutical import market.

Libya Gazette